FDA Has Concerns About Study of Atricure for Irregular Heartbeat

U.S. regulators said they’re concerned about a study on AtriCure Inc. (ATRC)’s alternative during open-heart surgery to treat an irregular heartbeat.

The device system from the West Chester, Ohio-based company to destroy heart tissue during surgery is set to be considered by a Food and Drug Administration advisory panel on Oct. 26.

To contact the reporter on this story: Anna Edney in Washington at aedney@bloomberg.net

To contact the editor responsible for this story: Adriel Bettelheim at abettelheim@bloomberg.net

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.